WuXi Biologics to build biomanufacturing facility in Ireland

WuXi Biologics is set to invest $392 million to build a new biologics drug substance manufacturing facility in Ireland. The new facility will use single-use bioreactors for commercial biomanufacturing.

This is also WuXi Biologics’ first manufacturing site outside of China. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will be installed. This facility will create approximately 700 jobs during its construction and over 400 highly skilled jobs after establishment over 5 years. 

Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.

Register as Visitor to CPhI China 2018!